Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Rapid Responses to:
|
|
Rapid Responses published:
|
|
|||
|
oscar,m jolobe, retired geriatrician manchester medical society, c/o john rylands university library, oxford road, manchester M13 9PP
Send response to journal:
|
Over and above the reasons for inclusion of trimethoprim in the prescription only category(1), I would add the risk of hyperkalaemia when standard doses of trimethoprim are administered to elderly patients with impaired renal function(2), especially when this co-exists with diabetes- related hyporeninemic hypoaldosteronism(3). In some of these elderly patients, the risk of hyperkaleamia may be increased by coprescription of angiotensin converting enzyme inhibitors(2). Co-prescription of sulfamethoxazole does not, however, appear to contribute to the risk, and it is recognised that trimethoprim is the culprit drug causing hyperkalaemia even in this context(4). Trimethoprim-related hyperkalaemia is attributable to the inhibition of amiloride-sensitive channels in the distal nephron with resulting impairment of kaliuresis(5). References (1) Howe R Don't include trimethoprim British Medical Journal 2008:336:787 (2)Marinella MA Trimethoprim-induced hyperkalemia: An analysis of reported cases Gerontology 1999:45:209-12 (3) Margassery S., Bastani B Life-threatening hyperkalemia and acidosis secondary to trimethoprim- sulfamethoxazole treatment Journal of Nephrology 2001:14:410-14 (4) Perazella MA Trimethoprim-induced hyperkalemia Drug Safety 2000:22:227-36 (5) Schlanger LE., Kleyman TR., Ling B K+ sparing diuretic actions of trimethoprim: inhibition of Na+ channels in A6 distal nephron cells Kidney International 1994:45:1070-6 Competing interests: None declared |
|||